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et al., 2008) in a manner regulated by neuronal RNABPs (Licatalosi 
et al., 2008), and these are potential sites for controlling RNA turno-
ver or regulation by miRNAs in the synapse, as suggested by studies 
of Arc (Bramham et al., 2008) or CaMKII synaptic RNAs (Ashraf 
et al., 2006). However, an important unresolved question is whether 
information generated by regulation of alternative RNA processing 
is tagged at the time it is generated in the nucleus or whether the 
complexity of RNA generated there is handled independently in 
the synapse. One means of exploring this question is to ask whether 
the regulatory RNABPs regulating alternative RNA processing of 
speciﬁ  c transcripts also participate in their synaptic regulation.
Nova-1 and Nova-2 comprise a family of neuron-speciﬁ  c 
RNABPs targeted in a paraneoplastic syndrome in which inhibitory 
control of motor systems is affected (Musunuru and Darnell, 2001; 
Darnell and Posner, 2003; Darnell, 2006). Nova proteins regulate 
alternative splicing in neurons (Jensen et al., 2000; Polydorides 
et al., 2000; Dredge and Darnell, 2003; Dredge et al., 2005; Ule 
et al., 2006, 2005; Licatalosi et al., 2008). In vitro, Nova binds an 
intronic YCAY-rich element in GlyRα2 pre-mRNA upstream of 
the mutually exclusive exons 3A (E3A) and E3B (Buckanovich 
and Darnell, 1997; Polydorides et al., 2000), and in co-transfec-
tion minigene assays this leads to preferential utilization of E3A 
(Jensen et al., 2000). It was subsequently recognized that Nova 
INTRODUCTION
Posttranscriptional regulation is thought to play a crucial role in 
generating diversity in the postsynaptic dendrite. This includes 
links between RNA splicing, RNA localization, RNA translation 
and synaptic formation, long term potentiation and synaptic plas-
ticity (Schuman et al., 2006; Sutton and Schuman, 2006; Lin and 
Holt, 2007; Richter and Klann, 2009). In some cases speciﬁ  c RNA 
binding proteins (RNABPs) have been correlated with this regula-
tion, including actions of FMRP (Bassell and Warren, 2008), ZBP 
(Rodriguez et al., 2008), Nova (Huang et al., 2005; Ule and Darnell, 
2006), CPEB (Richter, 2007) and others (Richter and Klann, 2009). 
In other cases, regulation of RNA metabolism, such as activity-
dependent alternative splicing and localization of NMDA recep-
tor subunits (Ehlers et al., 1995; Mu et al., 2003), has been clearly 
deﬁ  ned, but the factors directly involved are only now beginning 
to be deﬁ  ned (Ule and Darnell, 2006).
Studies in Drosophila and tissue culture cells suggest that splic-
ing may be mechanistically coupled to mRNA localization in the 
cytoplasm (Pinol-Roma and Dreyfuss, 1992; Luo and Reed, 1999; 
Kataoka et al., 2000; Le Hir et al., 2000; Hachet and Ephrussi, 
2004). There is also emerging interest in the role of the 3′ UTR in 
RNA regulation in the synapse (Holt and Bullock, 2009). Neurons 
have been found to generate preferentially long 3′ UTRs (Wang 
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FIGURE 1 | Subcellular distribution of Nova proteins. (A) Immunoblot 
analysis of Nova distribution in cytoplasmic and nuclear fractions from mouse 
brain (equal volumes (20 µl) of each fraction were loaded in lanes 1 and 2; 
equal protein amounts (50 µg) were loaded in lanes 3 and 4). Hsp90 is used as 
a cytoplasmic marker, and brPTB as a nuclear marker. The antibody used 
detects both Nova 1 (∼55 kD) and Nova-2 (∼75 kD) isoforms. (B) Nova signal is 
detected within the nucleus, somatic cytoplasm, and neurites of ventral horn 
spinal cord neurons. Within neurites, the signal is observed along the plasma 
membrane (arrowheads). Scale bar: 10 µm (B).
regulates numerous transcripts encoding synaptic proteins in the 
spinal cord and brain. Nova-null mice show defective splicing of 
inhibitory GlyRα2 receptors (Jensen et al., 2000), GABAA receptors 
(Dredge and Darnell, 2003), the Nova-1 transcript itself (Dredge 
et al., 2005), and the neuron-speciﬁ  c isoform of agrin (Ruggiu et al., 
2009). More generally, a combination of genome-wide screens for 
Nova targets, including exon junction arrays (Ule et al., 2005) and 
RNA-protein crosslinking (CLIP) methods (Ule et al., 2003, 2005; 
Jensen and Darnell, 2008; Licatalosi et al., 2008) coupled with addi-
tional biochemical and bioinformatic validation studies (Ule et al., 
2006) (reviewed in Licatalosi and Darnell, 2010) have conﬁ  rmed 
that Nova binds to YCAY-rich elements to regulate alternative splic-
ing of a biologically coherent set of transcripts encoding synaptic 
proteins (Ule et al., 2005; Ule and Darnell, 2006).
Not all Nova-RNA targets are regulated at the level of alterna-
tive splicing. Nova is also able to bind 3′ UTR elements to regulate 
alternative polyadenylation (Licatalosi et al., 2008), although other 
actions are less clear. For example, inhibitory responses to LTP 
(sIPSC of LTP) in the hippocampus were found to be dependent on 
Nova and on two of its target RNAs, encoding GIRK2 and GABAB 
receptors (Huang et al., 2005), but the consequence of Nova binding 
to those transcripts is unknown. In motor neurons, Nova regulates 
Z+ agrin splicing, but rescuing this activity failed to restore the abil-
ity of motor neurons to innervate muscle, and suggested additional 
defects proximal to the motor axon (Ruggiu et al., 2009).
The mounting evidence that nuclear RNA processing may also be 
coupled to RNA regulation in the cytoplasm, coupled with the detec-
tion of some Nova immunoreactivity in neuronal soma (Buckanovich 
et  al., 1996; Polydorides et  al., 2000), prompted us to investigate 
whether Nova might also act outside the nucleus. Here we show the 
existence of an abundant pool of cytoplasmic Nova. In tissue culture, 
Nova shuttles between the nucleus and cytoplasm, and it is required 
for RNA localization of the target GIRK2 mRNA in primary neu-
rons. In vivo, the Nova target GlyRα2 mRNA is well documented to 
be transported to spinal motor neuron dendrites (Racca et al., 1997, 
1998). We show that Nova is robustly detected in spinal motor neuron 
dendrites and, speciﬁ  cally, in inhibitory (gephyrin positive) synapses. 
Moreover, Nova co-localizes there with GlyRα mRNAs in spinal neu-
rons, both in dendrites and beneath synapses, but is excluded from 
dendrites in the dorsal horn where GlyRα mRNAs do not extend into 
the dendritic tree (Racca et al., 1998). Finally, biochemical analysis 
using CLIP identiﬁ  es binding sites in the GIRK2 3′ UTR, and we ﬁ  nd 
that Nova binding there is necessary for proper localization of GIRK2 
mRNA in neuronal processes. Taken together, these data demonstrate 
that the splicing factor Nova and its nuclear RNA targets are also co-
localized in dendrites close to synaptic contacts, suggesting a model 
in which the regulation of alternative splicing is coupled in cis to the 
expression of the same RNA in neuronal dendrites.
RESULTS
NOVA LOCALIZATION AND SHUTTLING BETWEEN THE NUCLEUS 
AND CYTOPLASM
To assess whether signiﬁ  cant amounts of Nova protein are present in 
the brain outside of the nucleus, we performed Western blot analysis 
of nuclear and cytoplasmic fractions of mouse brain. Nova protein 
was readily detectable in both fractions, with the majority (∼60%, 
normalized to total protein) present in the nucleus (Figure 1A), 
consistent with its role as a nuclear splicing factor and the high 
concentration of nuclear Nova evident by immunoﬂ  uorescence 
(below). Interestingly, when we normalized our input by loading 
equal volumes of brain cytoplasm and nuclear fractions, a measure 
of the total amount of Nova present in each, we found that two 
thirds (68%) of total Nova protein is present in the cytoplasm 
(Figure 1A). Immunoﬂ  uorescence microscopy using anti-Nova 
antibodies conﬁ  rmed an abundance of Nova immunoreactivity 
both within and outside of the nucleus (Figure 1B). Taken together, 
these data demonstrate very signiﬁ  cant amounts of Nova protein 
are present outside of the nucleus in mouse brain.
We asked whether Nova, like many RNABPs with this distribu-
tion, actively shuttles between the nucleus and cytoplasm. We assayed 
whether Nova endogenously expressed in a human neuroblastoma 
cell line (IMR-32) could shuttle into the nuclei of COS7 cells, an assay 
originally developed to document hnRNP-A1 shuttling (Pinol-Roma 
and Dreyfuss, 1992). Four hours after fusion, with de novo protein 
synthesis blocked, Nova appeared in the COS7 cell nuclei (Figure 2A). 
We repeated these experiments with fusions of another human neu-
roblastoma cell line [SK-N-BE(2)] and mouse 3T3 cells, again ﬁ  nding 
shuttling of endogenous Nova but not hnRNP-C1, a non-shuttling 
nuclear RNA binding protein (Figure 2B). We also conﬁ  rmed these 
results using an overexpressed Flag epitope-tagged Nova protein after 
transfection into HEK293 T cells and fusion to the neuroblastoma 
line N2A (data not shown). Taken together, these data indicate that, 
in tissue culture cells, Nova acts as a shuttling protein.
To investigate whether speciﬁ  c Nova protein domains regulate its 
subcellular localization, we examined the localization of Flag-tagged 
Nova constructs harboring deletions in either putative nuclear 
localization sequences (NLS) or nuclear export sequences (NES) 
(based on sequence homology with known motifs; Figure 2C). 
Wild-type Flag-Nova was localized primarily to the nucleus of 
transfected COS7 cells, with some staining evident in the cytoplasm. 
In contrast constructs in which the putative NLS was deleted were 
localized in a reticular pattern in the cytoplasm, and constructs in Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 3
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axial core and accumulate at dendritic branch points (Figure 1B; 
see also Figures 4A,B). The ultrastructural localization of Nova 
within neurons was investigated using pre- and post-embedding 
electron microscopy (EM) immunocytochemistry. EM conﬁ  rmed 
the nuclear and cytoplasmic localization of Nova. Neuronal nuclei 
were heavily stained by Nova (Figure 3A). Nuclear chromatin can 
be either highly condensed and scattered within the nucleoplasm 
or relaxed, depending on the neuronal subtype (Peters et al., 1991). 
which the putative NES was deleted were localized exclusively in 
the nucleus (Figure 2D). These observations deﬁ  ne distinct Nova 
domains that harbor NLS and NES activity.
These observations led us to examine Nova distribution in spi-
nal motor neurons in greater detail. We found that the dendrites 
of most of the neurons in the intermediate zone and ventral horn 
were strongly immunopositive for Nova. Dendritic staining had a 
punctate pattern and tended to localize peripherally to the dendritic 
FIGURE 2 | Nova proteins shuttle between the nucleus and cytoplasm. 
(A) IMR32 and COS7 cells were fused with PEG 3350, and anti-hnRNPC1 and 
anti-Nova antibodies were used to detect endogenous proteins. In this ﬁ  eld one 
cell has been fused with COS7 (top; see phase contrast, right panel), and two 
unfused cells are evident (bottom); cell types can be distinguished with DAPI 
staining (middle panel). Nova proteins were detected in IMR32 and fused COS7 
cells (arrowheads), but no signal in isolated COS7 cells. DAPI staining showed 
IMR32 cells and COS7 cells, respectively. (B) Shuttling of endogenous Nova from 
SK-N-BE(2) neuroblastoma cells into mouse NIH 3T3 cells; Nova, hnRNP-C12 and 
DAPI stains are shown as in (A). (C) Schematic of Flag-tagged Nova NLS and NES 
domains and deletion constructs generated. (D) COS7 cells were transfected with 
the indicated Flag-Nova1 plasmid constructs and stained with anti-ﬂ  ag antibody to 
visualize ﬂ  ag-Nova1 (top panels), and DAPI to visualize nuclei (bottom panels). 
Nova1 can be seen in the cytoplasm in cells transfected with the WT (left panel; 
arrows) but not in cells transfected with the ΔNES construct (right panel); in 
contrast the ΔNLS construct is largely excluded from nuclei (middle panel).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 4
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In neurons where the chromatin was relaxed (Figures 3A,B), Nova 
signal was not associated with any identiﬁ  able intranuclear struc-
tures. In contrast, in nuclei where the chromatin was highly con-
densed, especially when apposed to the nuclear membrane, Nova 
immunoreactivity was concentrated over these chromatin-dense 
regions (Figure 3C). In post-embedding experiments, Nova immu-
noreactivity was often observed near and within nuclear pores 
(Figure 3C). In the somatic cytoplasm, the labeling was scattered 
and tended to be in proximity of or associated with cisternae of 
the endoplasmic reticulum. Nova immunoreactivity could also be 
observed close to postsynaptic specializations (Figures 3A,D,E). 
Within dendrites, Nova was mainly peripheral along the plasma 
membrane, in the proximity of synaptic contacts (Figures 3D,E).
NOVA IS PRESENT AT INHIBITORY SYNAPSES
Immunoelectron microscopy for Nova (Figures 4A,B) and double-
immunoﬂ  uorescence for Nova and synapsin (Figures 4A,B insets), 
a presynaptic marker (Bloom et al., 1979; De Camilli et al., 1979, 
1983), conﬁ  rmed the presence of Nova protein at synapses. To assess 
whether Nova protein was present at inhibitory synapses, we exam-
ined whether Nova and gephyrin reactivity co-localized. Gephyrin 
is considered a postsynaptic marker of inhibitory synapses (Triller 
et al., 1985, 1987; Altschuler et al., 1986). Both immunoﬂ  uoresence 
and immuno EM demonstrated that Nova immunoreactivity is 
present in the somato-dendritic cytoplasm of postsynaptic inhibi-
tory differentiations identiﬁ  ed by a strong labeling for gephyrin 
(Figures 4C–E and inset).
LOCALIZATION OF NOVA-RNA TARGETS
Nova binds to GlyRα2 pre-mRNA to regulate alternative splic-
ing within the nucleus (Buckanovich et al., 1996; Buckanovich 
and Darnell, 1997; Jensen et al., 2000). To examine whether Nova 
might play a role in the regulation of mRNAs within dendrites, we 
took advantage of the observation that GlyRα2 mRNA is present 
at inhibitory synapses and in dendrites (Racca et al., 1997). Co-
  staining of spinal cord motor neurons for Nova proteins and 
FIGURE 3 | Ultrastructural localization of Nova in the somata and dendrites 
of ventral horn spinal cord neurons. (A,B) Micrographs of pre-embedding 
immunocytochemistry experiments. (C) Micrograph of a post-embedding 
immunocytochemistry experiment. (A) Distribution of Nova visualized with 
electron dense HRP reaction product (arrows). The nucleus is heavily stained but 
not the nucleolus (n). Presence of electron dense HRP reaction product 
(arrowhead) in front of a synaptic contact (b). (B) Gold particles associated with 
Nova are found within the nucleus (N), as well as within the somatic cytoplasm 
(arrows). (C) High magniﬁ  cation micrograph of the nuclear periphery. In spinal 
neuron nuclei (N), where the chromatin is condensed at the nuclear periphery in 
proximity of the inner side of the nuclear membrane, Nova (15 nm gold particles) 
accumulates over chromatin (crossed arrows) and can be found within nuclear 
pores (arrow). (D,E) Electron microscopic immunolabeling of Nova in dendrites 
(HRP reaction product) showing Nova tendency to accumulate peripherally to 
the dendritic center, and close to synapses (arrowheads). Axons are devoid of 
staining. Boutons (b). Scale bar: 4 µm (A); 2 µm (B); 0.3 µm (C); 1 µm (D,E).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 5
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GlyRα2 mRNA by EM and ﬂ  uorescence microscopy revealed that 
Nova protein co-localizes with GlyRα2 mRNA in the dendrite 
(Figure 5). GlyRα2 and GlyRα1 mRNA have previously been 
shown to co-localize (Racca et al., 1997), and we found that Nova 
protein and GlyRα1 mRNA also co-localize (Figure 5A). In the 
dorsal horn of the spinal cord, GlyRα2 mRNA transcripts do not 
translocate to dendrites, but are restricted to the neuronal somata 
(Racca et al., 1998). Interestingly, in these neurons Nova immuno-
reactivity was restricted to somata as well (Figure 5C).
Electron microscopy conﬁ  rmed that Nova protein and GlyRα2 
mRNA are co-localized within dendrites of spinal cord motor 
neurons. Here, as previously reported (Racca et al., 1997), subsy-
naptic GlyRα mRNA was often detected in association with small 
cisternae (Figures 5E,G) belonging to a protein synthesis-related 
subsynaptic apparatus (Gardiol et al., 1999), and this mRNA again 
co-localized with Nova protein. GlyRα2 mRNA and Nova pro-
tein were also associated with postsynaptic differentiations in 
the vicinity of these minute subsynaptic cisternae, suggestive of 
a protein synthesis-related subsynaptic machinery, and consistent 
with the nature of GlyRα2 proteins as transmembrane proteins 
(Figures 5D–G).
The spinal cord of Nova-null mice show defects in  alternative 
splicing of RNAs encoding synaptic proteins (Ule et al., 2005). To 
explore whether Nova-RNA targets are mislocalized in Nova-null 
neurons, we established primary neuronal cultures from E18.5 
embryos of WT and Nova1/2 null (“DKO”) mice. Interestingly, 
although GlyRα2 transcripts are localized in spinal motor 
neurons in adult animals (Racca et al., 1997, 1998), both this 
localization and the level of transcript expression (Kuhse et al., 
1991; Malosio et al., 1991) is developmentally regulated such 
that mRNA localization does not become evident until after the 
second postnatal week (C. Racca, unpublished data). Since Nova 
DKO mice die at birth (Ule et al., 2006; Ruggiu et al., 2009), 
Nova1 null animals die in the ﬁ  rst 7–10 days postnatally (Jensen 
et al., 2000) and Nova2 null animals usually die in the second 
postnatal week, we examined mRNA localization of a different 
Nova target.
We have previously shown that the ability of GIRK2 to mediate 
potentiation of slow inhibitory postsynaptic currents is Nova-
dependent (Huang et al., 2005). While the mechanism of Nova 
action on GIRK2 mRNA has not been determined, Nova CLIP data 
(Ule et al., 2003) previously indicated that Nova directly binds to 
FIGURE 4 | Localization of Nova at inhibitory synapses. (A,B) Nova signal 
detected by gold labeling (arrows) is observed in dendrite and opposed to boutons 
(b) at the dendritic periphery (arrowheads). Insets in (A) and (B), 
Double-immunoﬂ  uorescence detection of Nova (in red) and synapsin (in green) 
show that Nova immunoreactivity is present opposite to synaptic contacts 
(arrowheads). (C,D,E) Simultaneous detection of Nova and gephyrin 
immunoreactivity within the postsynaptic cytoplasm. Nova immunoreactivity 
(10 nm gold particles; arrows) is found beneath postsynaptic regions where 
gephyrin immunoreactivity (15 nm gold particles; arrowheads) decorates and 
identiﬁ  es inhibitory synapses. (D) High magniﬁ  cation of the postsynaptic 
cytoplasm of (C). Inset in (C), Double-immunoﬂ  uorescence of Nova (in green) and 
gephyrin (in red) showed that Nova immunoreactivity is observed in proximity of 
gephyrin immunoreactivity synaptic contacts (arrowheads). Scale bar: 0.2 µm (A); 
0.6 µm (B); 0.2 µm (C,E); 0.4 µm (D); 9 µm (insets in A,B); 6 µm (inset in C).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 6
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GIRK2 intronic pre-mRNA (intron 2). Moreover, GIRK2 mRNA 
has multiple isoforms, including at least three different alterna-
tive 3′ UTRs, which we conﬁ  rmed by RT-PCR (data not shown). 
To address which, if any, of these isoforms Nova might directly 
bind to, we searched a robust map of Nova-RNA interactions in 
the brain developed using HITS-CLIP (Licatalosi et al., 2008). 
This revealed a cluster of Nova CLIP tags (representing in vivo 
protein-RNA binding) within the distal-most 3′ UTR of GIRK2 
mRNA (isoform GIRK2-1; see Materials and Methods), which 
was enriched in the Nova binding element YCAY (Figure 6A). 
Additional upstream binding sites were also present in the GIRK2 
transcript, most notably in the intronic region between the 
FIGURE 5 | Nova and GlyRα2 mRNAs, its nuclear alternative splicing RNA 
target, colocalize outside the nucleus within dendrites. Fluorescence labeling 
for Nova immunoreactivity (in green; A,B,C) and ISH signal (in red) for GlyRα1 (A1) 
or GlyRα2 mRNAs (B1,C1). (A) Within the somatic and dendritic cytoplasm of 
ventral horn neurons, GlyRα1/2 (A1,B1) mRNAs and Nova (A,B) labeling co-
localizes (in yellow; A1,B1). The labeling pattern of Nova mirrors that of GlyRα1/2 
mRNAs. Both are also unevenly distributed within the dendritic cytoplasm and 
sometimes accumulate at the dendritic periphery (A,B; arrowheads) and branch 
points (B; arrows). Note that the signal corresponding to Nova protein or GlyRα1/2 
mRNAs are separated in some areas. (C) in neurons of the dorsal horn, where 
GlyRα2 mRNA (C1) is restricted to the somatic cytoplasm, Nova immunoreactivity 
is detected in nuclei (N) and to a lesser extent in somatic cytoplasm (C) resulting in 
a less accentuated co-localization (C2). (D–G) Ultrastructural simultaneous 
detection of Nova immunoreactivity and GlyRα2 mRNAs. Nova (HRP 
immunolabeling) and GlyRα2 mRNA ISH signal (gold particles) colocalize within 
the dendritic cytoplasm (arrows) and in front of synaptic boutons (arrowheads, b). 
Note in (E,G) the association of Nova and mRNA signals with small cisternae. 
Scale bar: 15 µm (A–C); 0.2 µm (D–F); 0.35 µm (G).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 7
Racca et al.  Nova localization with RNA targets
  annotated GIRK2a-1 and GIRK2-1 3′ UTRs, and in the intron 2 
site previously identiﬁ  ed (∼187,000 nt upstream of the 3′ UTR). 
We conﬁ rmed that Nova was bound to the mature GIRK2 mRNA 
in neuronal cytoplasm by repeating CLIP in a cytoplasmic brain 
fraction (data not shown and Figure 6A). The protein and tran-
script levels of GIRK2 remained unchanged in WT compared to 
Nova DKO brain (unpublished data). Taken together, these data 
suggested that Nova might act upon the GIRK2 3′ UTR element 
to regulate mRNA localization.
We therefore set out to examine localization of the GIRK2-1 iso-
form in neurons. We assessed GIRK2 mRNA localization using a set 
of Cy3-conjugated oligonucleotide probes directed at the GIRK2-1 
FIGURE 6 | Nova regulates localization of the CLIP target GIRK2-1 mRNA 
isoform in dendrites. (A) Location of Nova1 CLIP tags in the 3′ UTR of the GIRK2-
1 transcript. The RNA sequence of the GIRK2-1 3′ UTR in the region of the Nova 
binding site is shown, with YCAY elements highlighted in red. CLIP tags from 
mouse cortex (Nuc/Cyt) or cytoplasmic extracts of mouse brain (N1 cytoplasm) 
are shown separately. Nova tags are colored, with each color representing tags 
from a different mouse brain. Several other robust Nova CLIP target sites rich in 
YCAY elements were found in upstream sites, most notably in intron 2 ∼187 ,000nt 
upstream (see text). (B,C) Fluorescence ISH (FISH) using GIRK2-1 speciﬁ  c probes 
to detect mRNA in WT (B) or Nova DKO (C) primary cultured neurons obtained 
from E18.5 mouse cortex. No signal was seen with control ISH probes. 
(D) Comparison of GIRK2-1 FISH and MAP2 immunoreactivity in WT and Nova 
DKO primary neurons, as indicated. (E) Quantitation of ﬂ  uorescence intensity 
from (D); MAP2 ﬂ  uorescence signal was counted beginning 5–10 µm from the 
cell body and extended to the distal dendrites, and then the signal from GIRK2-1 
was obtained from the same dendrite; at least 10 neurons were counted in each 
of three experiments. The results from a three independent experiments are 
plotted as the sum of the dendritic signal from GIRK2-1 (Cy3) divided by MAP2 
(Cy5); error bars represent standard deviation (p < 0.05; Student’s t-test). The 
MAP2 signal alone was not signiﬁ  cantly changed in WT vs. KO neurons (data not 
shown). Sense strand oligonucleotides were used as a negative control and 
showed no signal under identical conditions. Scale bar: 10 µm (D).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 8
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mouse CLIP experiments, from a variety of tissues, including neo-
cortex, hippocampus and spinal cord) was identiﬁ  ed harboring 
13 YCAY elements within 1123 nucleotides (see Figure 6 legend). 
These data suggest a model in which intronic loading of Nova in 
the nucleus may couple regulation of pre-mRNA RNA metabolism 
(e.g. splicing) to 3′ UTR loading and regulation of mRNA expres-
sion (e.g. mRNA localization; Figure 9).
DISCUSSION
Nova functions as a neuron-speciﬁ  c alternative splicing factor 
(Jensen et al., 2000; Dredge and Darnell, 2003; Ule et al., 2003; 
Dredge et al., 2005; Licatalosi et al., 2008), but we ﬁ  nd here that the 
amount of Nova in the soma-dendritic compartment is at least as 
great as that in the nucleus. In ventral horn motor neurons, Nova 
proteins are localized within the nucleus, cytoplasm and dendrites 
and were often apposed to inhibitory synapses. Nova regulates the 
splicing of GlyRα2 mRNA (Buckanovich and Darnell, 1997), a 
transcript known to be transported to the dendrites (Racca et al., 
1997), and we ﬁ  nd here that Nova protein and GlyRα mRNA co-
localize within the dendrite (Figure 5), consistent with the ﬁ  nding 
that Nova binds directly to GlyRα pre-mRNA and 3′ UTR within 
the brain. In addition, Nova was required for proper localization 
of GIRK2 mRNA in primary neuronal cultures. Taken together, 
these observations suggest that the role of Nova in RNA regulation 
goes beyond its actions in the nucleus, such that it is able to act to 
coordinate nuclear RNA processing with local mRNA expression. 
Moreover, since Nova is critical for the normal physiology of motor 
neurons (Ruggiu et al., 2009) and hippocampal neurons (Huang 
et al., 2005), and at least in motor neurons, correction of a Nova-
dependent Z+ agrin splicing defect failed to rescue the physiologic 
defect (paralysis) in Nova DKO mice, it is possible that such actions 
may play critical roles in CNS neurons.
NOVA PROTEINS AND THE INHIBITORY SYNAPSE
Nova proteins are the neuron-speciﬁ  c target antigens in a paraneo-
plastic neurological disorder, Paraneoplastic Opsoclonus Myoclonus 
and Ataxia (POMA; Darnell and Posner, 2006). Clinically, POMA 
symptoms suggest an impairment of CNS inhibition. Interestingly, 
these clinical observations correlate with the ﬁ  nding that Nova 
proteins bind to introns, exons and UTRs of many RNAs encoding 
components of the inhibitory synapse [e.g. subunits of the GlyR and 
GABAA and GABAB receptors, gephyrin, GIRK2 and others (Jensen 
et al., 2000; Dredge and Darnell, 2003; Ule et al., 2003, 2005; Ule and 
Darnell, 2006; Licatalosi et al., 2008)]. GlyRα2 subunit and gephy-
rin mRNAs encode components of the inhibitory glycinergic syn-
apse (Moss and Smart, 2001). GIRK2 encodes a G protein-activated 
inwardly rectifying K+ channel that mediates GABAB inhibition in 
a Nova-dependent manner. We have found a physiologically rel-
evant action of Nova that appears to be speciﬁ  c to one alternatively 
processed GIRK2 isoform. Nova binds to a YCAY element in the 
GIRK2-1 3′ UTRs and localizes GIRK2-1 mRNA, but we found no 
evidence for Nova-dependent localization of other GIRK2 mRNA 
isoforms (data not shown). These data are most consistent with a 
model in which Nova binds to a 3′ UTR element to mediate mRNA 
localization, as observed for many other protein-RNA interactions 
(Kislauskis and Singer, 1992; Bassell and Singer, 2001; Palacios and 
St Johnston, 2001; Martin and Ephrussi, 2009).
3′ UTR extension in Nova WT and KO neurons. These probes did 
not yield a sufﬁ  cient signal:noise to detect GIRK2 RNA isoforms in 
E18.5 brain sections (perhaps due to low expression of the GIRK2 
and GIRK2-1 isoform; for example, as assessed by Affymetrix arrays 
of E18.5 mouse brain, the transcript normalized probe intensity for 
GIRK2 was 199, and for GIRK2-1 was ∼50, relative to a median of 708; 
data not shown). We therefore assessed GIRK2-1 mRNA localization 
in primary cultures of cortical neurons. These in situ hybridization 
(ISH) results demonstrated that GIRK2-1 mRNA extended from 
the cell soma into dendritic processes of WT neurons, where it was 
present in a punctate pattern. In contrast, in Nova DKO neurons, 
GIRK2 mRNA was restricted to the cell body and proximal dendrites, 
where it was present in a diffuse pattern (Figures 6B,C). Quantitation 
of the ﬂ  uorescence signal from GIRK2 mRNA in WT vs. Nova DKO 
dendrites, normalized to the immunoﬂ  uorescence signal from MAP2, 
demonstrated ∼ 3-fold decrease in dendritic GIRK2 mRNA in DKO 
neurons (p < 0.05; Figures 6D,E). We note also that mRNA appears 
to be more granular in WT compared to KO neurons; whether this 
relates to a role for Nova in mediating granule inclusion in dendrites 
for the localization of mRNAs it regulates is not known.
To address whether direct Nova binding to the GIRK2 3′ 
UTR (YCAY)4 element could localize the mRNA, we developed 
a reporter assay in N2A (neuroblastoma) tissue culture cells. We 
generated a construct encoding a destabilized d1EGFP (which has 
a short half life of ∼1 h, giving an image skewed toward detec-
tion of local protein expression) fused to a nuclear localization 
element (M9) and either a 208 nt fragment from the wild-type 
GIRK2 3′ UTR or a mutant 208 nt fragment which would abro-
gate Nova binding [in which the four YCAY repeats were mutated 
to YGUY; (Buckanovich and Darnell, 1997; Lewis et al., 2000); 
Figure 7A]. Expression of d1EGFP outside the nucleus was used 
as an indirect measure of GIRK2-1 mRNA localization. Cells 
transfected with the WT YCAY construct showed a clear and 
quantiﬁ  able increase in d1EGFP localization to distal neurites, 
while d1EGFP expression in cells transfected with the mutant 
YGUY construct was largely restricted to the cell body (Figures 
7B,C), while the d1EGFP signal in the soma was not signiﬁ  cantly 
changed. Interestingly, the T7-Nova signal also appeared more 
prominent in distal neurites in cells transfected with the WT 
YCAY construct, while the MAP2 signal was not changed, sug-
gest that direct Nova binding to GIRK2 3′ UTR is necessary for 
proper localization of the mRNA.
The action of Nova to regulate GlyRα2 pre-mRNA splicing 
and its co-localization with GlyRα2 mRNA suggests that protein 
may be bound to both GlyRα2 pre-mRNA and mature mRNA. 
We addressed this possibility by again examining Nova HITS-
CLIP data (Licatalosi et  al., 2008).  Figure 8A illustrates the 
intronic region of GlyRα2 pre-mRNA previously shown in vitro 
and in minigene assays to mediate Nova-dependent inclusion of 
E3A (Buckanovich and Darnell, 1997; Polydorides et al., 2000). 
Remarkably, the intronic Nova binding motif (YCAY clusters) is 
surrounded by several Nova CLIP tags (Figure 8A). In addition, 
examination of the 3′ UTR revealed several clusters of Nova CLIP 
tags, both around the stop codon and within the 3′ UTR itself 
(Figure 8B). This co-incidence of tags in the intron and 3′ UTR 
also led us to re-examine intronic tags in GIRK2 pre-mRNA; an 
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of glycine receptors at inhibitory synapses and, consequently, syn-
aptic function. More generally, the localization of Nova in the inhib-
itory synapse predicts the possibility that the physiology of these 
synapses may show Nova-dependent features, perhaps reﬂ  ected in 
the ﬁ  nding that inhibitory responses to LTP in the hippocampus 
are absent in Nova-null mouse brain (Huang et al., 2005).
In the nucleus, Nova binding to GlyRα2 pre-mRNA leads to prev-
alent expression of GlyRα2A subunit mRNA (Jensen et al., 2000). 
Both GlyRα2A and 2B subunit mRNAs are expressed prenatally in 
the CNS (Kuhse et al., 1990, 1991). After postnatal day 5 the expres-
sion of GlyRα2B subunit mRNA decreases, whereas the expression 
More is known about the action of Nova on the RNAs encoding 
the GABAA and GlyRα2 transcripts, where speciﬁ  c YCAY binding 
sites have been mapped within introns that mediate Nova-depend-
ent alternative exon usage (Buckanovich and Darnell, 1997; Jensen 
et al., 2000; Dredge and Darnell, 2003). Here we provide convergent 
data demonstrating that Nova is present in the nucleus and, along 
with GlyRα mRNAs and gephyrin, within the  dendrites and in the 
vicinity of inhibitory synapses in central neurons. These ﬁ  ndings 
suggest that Nova might provide a means to couple nuclear RNA 
binding to the dendritic and subsynaptic localization of GlyRα2 
mRNA. This could ultimately regulate the composition or number 
FIGURE 7 | Binding of Nova to the GIRK2-1 YCAY element is necessary for 
proper localization. (A) Schematic of a reporter encoding destabilized d1EGFP 
with an M9 nuclear localization sequence (NLS) and the 3′ UTR GIRK2-1 YCAY 
element. An identical construct in which the four YCAY sequences were 
mutated to YGUY was also made. (B) Comparison of EGFP and MAP2 
immunoreactivity in cells co-transfected with plasmid constructs encoding the 
YCAY or the mutant (“mut”) YGUY element, as indicated, and a construct 
expressing T7-tagged Nova. The WT Nova target mRNA (green channel, left 
panel) was localized in distal neurites in transfecting cells expressing the YCAY 
but not mutant GIRK2-1 element; T7-tagged Nova itself, detected with T7 
antibody (middle panel) also appeared more localized in distal dendrites, while 
MAP2 (right panel) was unchanged in either condition. (C) Quantitation of EGFP 
ﬂ  uorescence intensity from (B); Region of Interest (ROI) was chosen based on 
neurite in which MAP2 ﬂ  uorescence signal was detected, beginning 5 µm from 
the cell body and extending outwards. The signal from d1EGFP was obtained 
from the same ROI; more than 10 cells were counted. The results are plotted as 
relative ratio of the sum of the neurite signal from d1EGFP (Cy2) divided by 
MAP2 (Cy3) in YCAY element or mutated constructs; error bars represent 
standard deviation (p < 0.05); results are from three independent experiments. 
Scale bar: 10 µm (B).Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 10
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relationship between these disparate binding sites. GlyRα mRNA 
is a robust transcript for addressing this question for two reasons. 
Nova binding sites in intron 3 were necessary to mediate alterna-
tive splicing in minigene assays (Buckanovich and Darnell, 1997; 
Polydorides et al., 2000). At the same time, GlyRα mRNAs are 
among the best documented dendritically localized transcripts 
(Racca et al., 1998; Steward and Schuman, 2001). The subcellular 
localization of Nova within dendrites of ventral horn but not dor-
sal horn spinal cord neurons parallels the dendritic localization 
of GlyRα subunit mRNAs (Figures 5A–C). The co-localization of 
Nova protein, GlyRα2 and GIRK2 mRNA outside of the nucleus, 
together with HITS-CLIP data demonstrating direct Nova bind-
ing to GlyRα2 and GIRK2 intronic and 3′ UTR elements (Figures 
6 and 8) indicate a link between the nuclear and cytoplasmic 
actions of Nova. Nova interacts with each transcript both prior 
to nuclear processing, as pre-mRNA, and after processing and 
cytoplasmic transport.
One plausible scenario by which Nova regulates both GlyRα2 
pre-mRNA splicing and GlyRα2 mRNA localization/expression 
would be via independent binding to intronic and 3′ UTR elements, 
as suggested for the localization of oskar mRNA in Drosophila 
oocytes (Hachet and Ephrussi, 2004). Binding to both sites could 
also be linked within the nucleus, for example by co-deposition 
of Nova in cis on introns and 3′ elements of the same transcript. 
A more complex possibility invokes a direct link between the two, 
FIGURE 8 | Location of Nova CLIP tags in the GlyRα2 transcript. (A) The 
sequence of the previously characterized Nova binding YCAY motif upstream of 
GlyRα2 exon 3A is shown (blue); mutation of these YCAY elements (red) 
abrogates E3A splicing (Buckanovich and Darnell, 1997). Lower panel shows 
Nova HITS-CLIP tags in this intronic region. (B) Nova HITS-CLIP tags in the 
GlyRα2 3′ UTR. In (A,B) Nova tags are colored as in Figure 6.
level of GlyRα2A subunit mRNA is not altered (Kuhse et al., 1991). 
Interestingly, the localization of GlyRα subunit mRNAs to dendrites 
is also developmentally regulated and starts occurring after the second 
postnatal week (C. Racca, unpublished data). This observation meant 
that we focused our studies on adult animals, and were not able to 
study GlyRα2 subunit mRNA localization in Nova KO mice (which 
typically die in early postnatal life; Jensen et al., 2000). Nonetheless, the 
data suggest that the main form of GlyRα2 subunit mRNA present in 
dendrites is likely to be GlyRα2A, the one also favored by Nova-medi-
ated splicing. GlyRs containing either α2A or α2B subunit differ in 
their agonist sensitivity (Miller et al., 2004), such that those containing 
α2B subunit are more sensitive to agonists (glycine, alanine and tau-
rine) than are those containing α2A. Although yet to be proved, our 
data raise the possibility that neurons modulate their ligand sensitivity 
by local regulation, through Nova-mediated regulation of splicing, 
localization and/or expression of GlyRα2A mRNA.
SUBSYNAPTIC RNPs COULD BE ASSEMBLED IN THE NUCLEUS IN A 
SPLICING-DEPENDENT MANNER
Nova proteins were detected in the nucleoplasm, nuclear pores, and 
within the somato-dendritic cytoplasm, co-localized with target 
mRNAs. Although functional Nova binding sites were originally 
identiﬁ  ed as intronic elements, the protein also binds to exons 
and 3′ UTR regions of different RNAs (Darnell, 2006; Licatalosi 
et al., 2008). However, it has been unclear whether there is any Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 11
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involving remodeling of the Nova/GlyRα2 RNA-protein complex. 
In this scenario, Nova would bind directly to intronic sequences 
to mediate splicing, and then remain associated with the mature 
GlyRα2 mRNA. Although HITS-CLIP detects binding to introns 
that are common to multiple processed mature mRNA forms, 
because CLIP efﬁ  ciency is very low (only ∼1% of transcripts are 
cross-linked), it cannot distinguish whether Nova-RNA interac-
tions are present on pre-mRNA transcripts or a subset that are 
subsequently processed (in either alternative exons or poly(A) sites) 
in a speciﬁ  c manner. In addition, we note that not all 3′ UTRs har-
boring Nova tags showed evidence of Nova-dependent localization 
(MAP1B, for example; data not shown), consistent with the idea 
that Nova may mediate a variety of actions upon the 3′ UTRs of 
different mRNAs.
Multimerization of RNABPs in cis is thought to be important 
in the interaction of Rev with the RRE stem-loop of HIV (Malim 
and Cullen, 1991), and of hnRNP-A1 with the HIV-1 tat transcript 
to antagonize the action of some SR proteins (Zhu et al., 2001). In 
these instances, recognition of single high afﬁ  nity motifs is followed 
by lower afﬁ  nity multimerization of the RNABPs in cis on target 
RNAs to provide biologically important deposition of RNABPs 
in the area of the initial high afﬁ  nity binding site. Diffusion in 
cis along DNA is an analogous process clearly documented to be 
important in transcription factor dynamics, such that DNA binding 
proteins are believed to spend most of their time bound to DNA 
non-speciﬁ  cally searching for high afﬁ  nity binding sites present in 
cis (Elf et al., 2007; Gorman et al., 2007; Gorman and Greene, 2008; 
Visnapuu and Greene, 2009).
Such diffusion and multimerization around binding sites may 
be considered for Nova based on several observations: clusters of 
YCAY elements are seen in both the GlyRα2 and GIRK2 intronic 
and 3′ UTR elements (Figures 6 and 8), these are necessary for 
Nova-dependent action (splicing for GlyRα (Jensen et al., 2000) 
and localization for GIRK2-1, Figure 7), and clusters of binding 
elements may more generally be important to allow a sufﬁ  cient 
concentration of RNABPs for effector action (Martin and Ephrussi, 
2009). Although the results in overexpression transfection stud-
ies (Figure 7) were done with reporters that do not have introns, 
and therefore suggest that Nova binding the 3′ UTR can localize 
mRNA without prior intronic binding, the effects on localiza-
tion were smaller than that quantitated for native GIRK2-1 RNA 
localization (Figure 6), and do not preclude the possibility that 
intronic binding may precede localization in systems in which 
RNABP/RNAs are not overexpressed (i.e. in the nervous system). 
An interesting feature of a model in which Nova splicing is coupled 
to 3′ UTR deposition is that it predicts that Nova binding to pre-
mRNA might be directly coupled both to generation of a speciﬁ  c 
spliced isoform (e.g. GlyRα2-E3A mRNA), and to its subsequent 
somato-dendritic localization and protein expression (Figure 9). 
Assessment of this model will require careful biochemical mapping 
and coordination of key Nova binding sites from among the many 
identiﬁ  ed intronic and 3′ UTR binding sites identiﬁ  ed by HITS-
CLIP (Licatalosi et al., 2008).
Another, and not mutually exclusive factor that might inﬂ  uence 
Nova assembly with mature mRNA is through interaction with other 
RNABPs recruited onto the mature mRNA, as suggested for bicoid 
mRNA and several other localized RNAs (Arn et al., 2003; Martin 
and Ephrussi, 2009). Vegetal pole ribonucleoprotein particles assem-
bled in Xenopus oocyte nuclei change upon export to the cytoplasm, 
where the RNA-protein complexes can recruit new RNABPs (Kress 
et al., 2004). Such RNA-protein complexes are believed to be the sub-
strates of mRNA localization and are assembled by the recruitment 
of trans-acting factors, including motor proteins and the interaction 
of RNABPs with cis-acting sequences often situated in the 3′ UTR 
regions. These cis-acting sequences are believed to be sufﬁ  cient to 
mediate the localization of the mRNA (St Johnston, 2005). This view 
has been challenged by the demonstration that, at least in the case of 
oskar, splicing and 3′ UTR sequences are independent requirements 
for mRNA localization (Hachet and Ephrussi, 2004). Indeed, this and 
previous works (Hachet and Ephrussi, 2001; Palacios et al., 2004) 
suggest that cytoplasmic localization of an mRNA could be linked to 
the splicing-dependent deposition of RNABPs at the junction of the 
freshly assembled exons (Palacios, 2002; Giorgi and Moore, 2007). 
Hints of similar phenomenon are beginning to emerge from stud-
ies of mammalian ZBP RNABPs (ZBP1 with ZBP2, also known as 
KSRP), which are capable of localizing mRNAs harboring cis-acting 
sequences, and also interact with proteins implicated in regulating 
alternative splicing (Gu et al., 2002; Rodriguez et al., 2008). Thus the 
association of Nova with GlyR pre-mRNA may lead to deposition 
of factors that mark the mature mRNA with cis-acting RNABPs, 
presumably including Nova itself, that help direct the subsequent 
localization of the mRNA.
FIGURE 9 | Model of Nova action. Nova binds to pre-mRNA in the nucleus. 
This binding can, but need not be intronic (pathway labeled “1”). If binding sites 
are in the region of alternatively spliced exons, Nova can mediate alternative 
splicing, according to the rules of a functional binding map, such that the 
position of Nova binding determines the outcome of alternative exon inclusion. 
Subsequently, Nova may multimerize in cis upon the same transcript (pathway 
1), or may be independently deposited upon additional mRNA binding sites, 
such as those in the 3′ UTR (pathway labeled “2”). 3′ UTR binding sites may 
determine additional processing steps (such as mediating alternative 
polyadenylation), and mediate soma and dendritic mRNA localization (as in the 
case of GIRK2-1 and perhaps GlyRα2 mRNA). It is presumed, based for 
example on the studies of Singer and colleagues (Lawrence and Singer, 1986; 
Kislauskis et al., 1997; Rodriguez et al., 2008), that such RNA localization would 
be coupled to the regulation of translation. In neurons, coupling pre-mRNA 
binding to mRNA localization and translation offers the possibility of linking 
information content generated in the nucleus (alternative splicing or 
polyadenylation) with differential gene expression in dendrites.Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 12
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MATERIALS AND METHODS
NUCLEAR/CYTOPLASMIC FRACTIONATION METHOD
Brain tissue was Dounce homogenized in cold 10 mM HEPES (pH 
7.9), 10 mM NaCl, 1.5 mM MgCl2, 0.2% Triton X-100, 10 mM NaF, 
protease inhibitors (Roche) and spun at 3000 × g for 3 min. Supernatant 
was collected as cytoplasmic fraction, and pellet was resuspended 
in 20 mM HEPES (pH 7.9), 25% glycerol, 1.5 mM MgCl2, 1.4 mM 
KCl, 0.2 mM EDTA, 0.5% NP-40, 10 mM NaF, protease inhibitors 
(Roche) and 5% DNase, incubated 5 min at 37°C, dialyzed against 
1× PBS, pH 7.4, 1.5 mM MgCl2, 0.5% NP-40, 10 mM NaF, and col-
lected as nuclear fraction. Both fractions were diluted to the same ﬁ  nal 
volume and ultracentrifuged at 100,000 × g for 30 min.
IMMUNOBLOT ANALYSIS
Equal volumes (20 µl) or equal total protein amounts (50 µg) were 
loaded onto 10% SDS-PAGE gels, and transferred to PVDF mem-
branes (Millipore). Membranes were blocked and incubated with 
primary antibodies including rabbit anti-Nova (1:750) (Buckanovich 
and Darnell, 1997), mouse anti-Hsp90 (1:1000; Transduction labo-
ratories), and rabbit anti-brPTB (Polydorides et al., 2000).
OLIGONUCLEOTIDE PROBES
Oligonucleotide probes encoded: α1 residues 1050–1094 and 
1096–1143 (Grenningloh et al., 1987; Malosio et al., 1991; Racca 
et al., 1997, 1998); α2 residues 1682–1726 and 1789–1810 (Kuhse 
et al., 1990; Malosio et al., 1991; Racca et al., 1997, 1998).
PRIMARY ANTIBODIES
Different antibodies, all giving the same pattern of staining (data 
not shown), were used at appropriate concentrations depending 
on the experiment to detect Nova epitopes. Afﬁ  nity-puriﬁ  ed rabbit 
anti-Nova (Yang et al., 1998); human sera from POMA patients; 
afﬁ  nity-puriﬁ  ed human anti-Nova; mouse monoclonal antibody 
anti-gephyrin (Pfeiffer et al., 1984); rabbit anti-synapsin (Bloom 
et al., 1979; De Camilli et al., 1979).
Speciﬁ  c antibodies and concentrations used in each ﬁ  gure are 
listed:
Figure 1B: Single IC: anti-Nova human serum (1:1000); Goat 
anti-Human FITC (Jackson) 1:200
Figures 3A,D,E: anti-Nova Rabbit Puriﬁ  ed (1:750); Goat anti-
Rabbit Biotinylated (Vector) 1:200
Figure 3B: anti-Nova human serum (1:1000); Goat anti-Human 
Nanogold, 1 nm (Nanoprobrobes) 1:50
Figure 3C: anti-Nova Rabbit serum (1:200); Goat anti-Rabbit, 
15 nm Gold particle (British Biocell) 1:50
Figures 4A,B: anti-Nova human serum (1:1000); Goat anti-
Human Nanogold, 1 nm (Nanoprobrobes) 1:50
Figures 4C–E: anti-Nova Rabbit serum (1:400); Goat anti-
Rabbit, 10 nm Gold particle (British Biocell) 1:50 + anti-Gephyrin 
Mouse mAb (Boehringer Mannheim)1:100; Goat anti-Mouse, 
15 nm Gold particle (British Biocell) 1:50
Figure 4 inset in A and B: anti-Nova human serum (1:1000); 
Goat anti-Human FITC (Jackson) 1:200 + anti-Synapsin Rabbit 
Serum 1:6000; Goat anti-Rabbit Cy3 (Jackson) 1:200
Figure 4 inset in C: anti-Nova Rabbit Puriﬁ  ed (1:750); Goat anti-
Rabbit FITC (Jackson) 1:200 + anti-Gephyrin Mouse mAb (Boeringher 
Mannheim) 1:100; Goat anti-Mouse Cy3 (Jackson) 1:200
Figures 5A–C: anti-Nova Rabbit Puriﬁ  ed (1:750); Goat anti-
Rabbit FITC (Jackson) 1:200; and for ISH: Sheep anti-DIG 
(Boehringer Mannheim) 1:1000/donkey anti-Sheep Cy3 (Jackson) 
1:200
Figures 5D–G: anti-Nova human serum (1:200); Goat anti-
Human Biotinylated (Vector) 1:200 and for ISH Sheep anti-DIG 
Nanogold, 1 nm (Nanoprobrobes) 1:50
TISSUE PREPARATION
This study was performed in full accordance with the European 
Communities Council Directives (86/609/EEC) and the French 
national Committee (87/848) recommendations and the 
Rockefeller University Animal Care and Use Committee guide-
lines. Adult Sprague-Dawley rats (Janvier, France) were deeply 
anaesthetized with pentobarbital (60 mg/kg body weight, i.p.), 
and intracardially perfused. For ﬂ  uorescent immunocytochemis-
try and in situ hybridization (ISH) animals were perfused with 4% 
paraformaldehyde (PFA) in phosphate buffer saline (0.1 M, pH 
7.2; PBS). For EM immunocytochemistry and ISH animals were 
perfused with 4% PFA and 0.1% glutaraldehyde in PBS. Spinal 
cords were removed and postﬁ  xed in 4% PFA in PBS overnight 
at 4°C. Spinal cord sections were cut onto a vibratome and col-
lected in PBS.
FLUORESCENT IMMUNOCYTOCHEMISTRY ON SPINAL CORD SECTIONS
Spinal cord 30 µm sections were rinsed in 50 mM NH4Cl in PBS 
for 15min, and permeabilized with 0.1% Triton X-100, 0.1% 
bovine gelatin in PBS for 10 min. The primary antibodies were 
incubated in the same buffer overnight at 4°C. Sections were then 
rinsed in PBS (3 × 10 min each) and incubated for 2 h at room 
temperature (RT) with the corresponding ﬂ  uorescent secondary 
antibodies (carboxymethyl indocyanine (Cy3) or ﬂ  uorescein iso-
thiocyanate (FITC); Jackson ImmunoRes Labs (West Grove, PA, 
USA), in 0.1% bovine gelatin in PBS). After three washes in PBS 
(10 min each), sections were mounted on slides with Vectashield 
(Vector Lab.).
FLUORESCENT IN SITU HYBRIDIZATION AND 
IMMUNOCYTOCHEMISTRY ON SPINAL CORD SECTIONS
Fluorescent in situ hybridization (ISH) was as previously described 
(Racca et al., 1997, 1998). Digoxigenin labeled probes and Nova 
proteins were contemporaneously revealed in 100 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 2% BSA, 0.3% Triton X-100, overnight, 
4°C. The anti-digoxigenin and anti-Nova primary antibodies were 
detected by incubating sections with the appropriate secondary 
antibodies (in PBS, 2 h at RT). Each incubation was followed by 
three washes in PBS (10 min each). Finally, sections were mounted 
on slides with Vectashield (Vector Lab.)
IMAGE ACQUISITION
The sections processed for ﬂ  uorescent immunocytochemistry and 
ISH were observed with an epiﬂ  uorescent Zeiss microscope, or a 
Leica confocal laser scanning microscope. All images presented here 
were obtained with the Leica confocal laser scanning microscope. 
For confocal images the background noise was reduced by applying 
a Gaussian ﬁ  lter to the optical sections.Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 13
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ELECTRON MICROSCOPIC IMMUNOCYTOCHEMISTRY
100 µm thick vibratome sections were cryoprotected in 20% 
glycerol-20% sucrose in PBS, and permeabilized by freezing and 
thawing. Sections were collected in PBS, rinsed in 50 mM NH4Cl 
in PBS for 15 min, and 0.1% bovine gelatin in PBS for 10 min. 
The free-ﬂ  oating sections were incubated with the primary anti-
bodies in 0.1% bovine gelatin in PBS, overnight, at 4°C. The fol-
lowing day, sections were rinsed three times in PBS (10 min each) 
and incubated with the secondary antibodies (in PBS-1% BSA 
for biotinylated antibodies, 2 h RT or in PBS-0.2% ﬁ  sh gelatin 
for gold antibodies, overnight 4°C). Biotinylated antibodies were 
revealed with the ABC Elite kit (in PBS, 1 h, RT; Vector Lab) and 
the peroxidase reaction was carried out in the presence of DAB 
and hydrogen peroxide (Sigma Fast, Sigma Aldrich). Nanogold-
coupled antibodies were ampliﬁ   ed as described (Trembleau 
et al., 1994).
ELECTRON MICROSCOPIC PRE-EMBEDDING NON-RADIOACTIVE 
IN SITU HYBRIDIZATION AND IMMUNOCYTOCHEMISTRY
Fifty micrometer sections were cryoprotected and permeabilized 
as for EM immunocytochemistry. Prehybridization and hybridi-
zation were as described above for ﬂ  uorescent ISH. After the 
stringency washes, sections were rinsed in PBS and incubated in 
the primary antibody in 1% BSA in PBS, overnight, at 4°C. After 
three PBS rinses (10 min each), DIG molecules and the primary 
antibody were detected by gold- and biotin-coupled antibodies, 
respectively in 0.8% BSA, 0.2% Fish Gelatin in PBS, overnight, 4°C. 
After three PBS rinses (10 min each) sections were incubated in 
4% PFA in PBS (10 min), rinsed three times in PBS (10 min each) 
and several times in cold distillated water. Gold-coupled sheep 
anti-DIG secondary antibodies were detected by a silver enhance-
ment-gold toning protocol as described (Trembleau et al., 1994). 
After three PBS rinses (10 min each), biotinylated antibodies were 
detected by peroxidase-DAB reaction as in classical immunocy-
tochemical methods.
The sections processed for immunocytochemistry and ISH were 
dehydrated, osmicated and ﬂ  at embedded in araldite (Fluka) resin. 
Ultrathin sections were prepared, mounted in copper grids and 
contrasted with uranyl acetate and lead citrate before examination 
under a Jeol CX II transmission electron microscope at 80 kV.
ELECTRON MICROSCOPIC POST-EMBEDDING IMMUNOCYTOCHEMISTRY
Vibratome 200 µm thick sections were cryoprotected with 2 M 
sucrose in PBS, rapidly frozen in liquid propane, cryosubstituted 
and inﬁ  ltrated with HM20 resin (Polysciences, Germany) in a cryo-
substitution unit (AFS; Reichert). Polymerization was induced by 
UV light for 3 days, at −45°C. Ultrathin sections were prepared and 
mounted on formvar-coated 400 mesh nickel grids and processed 
for immunocytochemistry as follows. Sections were etched in a 
saturated sodium ethanolate solution for 2 s and rinsed in distilled 
H2O. After 10 min in 0.1% NaBH4, 50 mM Glycine in Tris Buffered 
Saline (TBS) (50 mM, pH 7.4, 50 mM TBS) the grids were rinsed by 
three washes of 50 mM TBS (10 min each). Grids were incubated 
in drops containing the primary antibodies in 50 mM TBS, over-
night or 48 h at 4°C. Unbound primary antibodies were removed 
by 50 mM TBS washes and by incubating grids in drops of TBS 
(10 min) and 150 mM TBS (10 min, three times each). Primary 
antibodies were revealed by immunoglobulins coupled to calibrated 
gold particles (10 and 15 nm; British BioCell Int.) in Polyethylene 
Glycol 20000 (5 mg/ml PEG), 2% BSA in 150 mM TBS, 2 h at 37°C. 
The sections were then rinsed several times in 50 mM TBS, and 
stabilized in 2% glutaraldehyde in 50 mM TBS. Finally, after several 
washes in H2O, the grids were contrasted with uranyl acetate and 
lead citrate and examined under a Jeol CX transmission electron 
microscope at 80 kV.
IMAGING CONTROLS
Sense and random oligonucleotide probes and omission of any 
oligonucleotide or primary antibody or any single major step in 
the development of DAB reactions, ﬂ  uorescent ISH and immu-
nocytochemistry resulted in no labeling of any cells. All the oligo-
nucleotide probes and antibodies used have been described and 
fully characterized previously (Malosio et al., 1991; Sato et al., 1991; 
Buckanovich et al., 1993, 1996; Racca et al., 1997, 1998). For double-
ﬂ  uorescence experiments, controls included either the independent 
omission of each single major step of the immunocytochemistry 
and/or ISH protocols, one at a time, or the replacement of the 
primary antibody by normal goat serum (Invitrogen; see Figure 
S1 in Supplementary Material).
NOVA CLIP
Nova cytoplasmic HITS-CLIP was performed as described pre-
viously (Licatalosi et al., 2008), with minor modiﬁ  cation. After 
the brain was UV-irradiated to covalently crosslink RNA-protein 
complexes, nuclear/cytoplasmic fractionation was performed as 
described above. In brief, extracts were then partially RNased to 
reduce the modal size of cross-linked RNA bound to Nova to ∼50 
nt. Extracts were immunoprecipitated with a Nova1-speciﬁ  c anti-
body (Millipore), RNA linkers added with T4 RNA ligase, com-
plexes puriﬁ  ed by SDS-PAGE, protein removed with proteinase 
K, and RNA sequenced by reverse transcription and sequencing 
with an Illumina Bioanalyzer. One brain was utilized for Nova1 
cytoplasmic CLIP which yielded total 1,504,346 tags, 815,172 of 
which were able to be mapped to the mouse genome and 48,518 of 
which mapped to unique locations. These unique tags were used for 
analysis of cytoplasmic Nova binding sites in GlyRα2 and GIRK2 
transcripts. Additional CLIP experiments used rabbit anti-Nova 
antibody to perform CLIP as described (Licatalosi et al., 2008), in 
biologic triplicate from mouse cortex (Figure 6A) and in biologic 
duplicate from mouse spinal cord (Figure 8B; Eom and Darnell, 
manuscript in preparation).
Nova HITS-CLIP binding sites were identiﬁ  ed in the GIRK2 dis-
tal-most 3′ UTR (GIRK2A or GIRK2-1 isoform; NM_001025584.2) 
using the UCSC genome browser. Similarly, the GIRK2 intron 
2 binding site identiﬁ  ed (∼187,000 nt upstream of the 3′ UTR) 
was: (>mm9, chr16:95160755-95160878: CCATTCCTTC 
ACTATCCACA GCCCAAAAGC TAAGTCCTAA TCTCTGCATC 
TTAAAGACCA ATGTAAATGA CCCATACATC ATCACCACCA 
TCATCTTCAT CTTTGTCATC ACTGTCCTCT TCAT).
HETEROKARYON ASSAYS
HEK293-T or COS7/NIH3T3 cells were plated on gelatin coated 
coverslips. For shuttling of overexpressed Nova, transfection was 
performed before plating IMR-32/SK-N-BE(2) cells. Fusion of Frontiers in Neural Circuits  www.frontiersin.org  March  2010 | Volume  4 | Article  5 | 14
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two different cells was induced by using 50% polyethylene glycol 
(PEG 3350; Sigma Aldrich) in water for 2 min. Cells were washed in 
PBS, and returned to medium containing 75 μg/ml cycloheximide 
for another 3 h incubation. Immunoﬂ  uorescence was followed by 
ﬁ  xation. HEK293-T, Neuro2a and COS7 cells were transfected 
with plasmid constructs by using Fugene6 (Roche) as described 
by manufacturer. After 24 h, the cells were ﬁ  xed in PFA (4% in 
PBS) at RT for 15 min.
CONSTRUCTS
T7-Nova1 have been described previously (Dredge and Darnell, 
2003). Flag-tagged ΔNLS-Nova1 and ΔNES-Nova1 were generated 
by PCR mutagenesis, deleting amino acids 25–40 and amino acids 
318–335, respectively. GIRK2 YCAY elements were ampliﬁ  ed by 
PCR and added into the pd1EGFP-N1 vector (Clontech). Mutations 
to YCAY elements were made by using QuickChange site-directed 
mutagenesis kit (Stratagene). In order to avoid effects from diffu-
sion, the M9-NLS was added into vector.
GIRK2 YCAY primers are listed in Supplementary Material.
IMMUNOFLUORESCENCE IN CULTURED CELLS
For detection of proteins, we used monoclonal antibodies to T7 
(Novagen), Flag (Sigma Aldrich) and hnRNP-C1 (generous gift 
from Dr. Piñol-Roma), and POMA serum for Nova proteins. All 
secondary antibodies were afﬁ  nity-puriﬁ  ed donkey antibodies 
to mouse or human IgG conjugated to a ﬂ  uorochrome (Jackson 
Immunoresearch). Antibody incubations were for 1 h at RT in TBS 
with BSA (1%) and Triton X-100 (0.1%). Coverslips were mounted 
with Prolong gold antifade reagent (Invitrogen). Primary neuronal 
cultures were generated from E18.5 cortical neurons prepared as 
described (Eom et al., 2003). Cells were ﬁ  xed at 14 DIV for immun-
oﬂ  uorescence staining with MAP2 monoclonal antibody (Sigma 
Aldrich) or FISH.
FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN CULTURED CELLS
Five amino-modiﬁ  ed oligonucleotide probes (approximately 50 
nts each; see Supplementary Material) were designed to mouse 
GIRK2 mRNA and synthesized on a DNA synthesizer incor-
porating ﬁ  ve  amino-modiﬁ   ed thymidines (C6dT), puriﬁ  ed 
and   chemically labeled using ﬂ  uorophores (Cy3; Amersham) 
as described (http://www.singerlab.org/protocols). In situ 
 hybridization was completed as previously described (Eom et al., 
2003). Coverslips were mounted with Prolong gold antifade rea-
gent (Invitrogen).
QUANTITATIVE ANALYSIS
For image acquisition, exposure times and other settings were kept 
constant within the same experiment. In order to avoid bias in quan-
titation, regions of interest (ROI) were ﬁ  rst chosen from ﬂ  uorescence 
images of MAP2 (a dendritic marker) and were then transferred onto 
the ﬂ  uorescent image of the same cell. The ROI was chosen 5–10 µm 
from the cell soma to speciﬁ  cally capture dendritic images. Total ﬂ  uo-
rescent intensities were collected from the same ROI for FISH, GFP 
or MAP2. A mask covering the dendrite was created based on MAP2 
signals, and the ﬂ  uorescent intensity signals of FISH or GFP was nor-
malized to that of MAP2. In FISH analysis, the Cy5 channel was used 
for MAP2 analysis, Cy3 for FISH analysis. In GFP analysis, the Cy3 
channel was used for MAP2 and Cy2 for GFP analysis. Quantitative 
analysis was performed by determining normalized ﬂ  uorescence 
(pixel) intensities in neurites. Student’s t-test was applied to measure 
statistical signiﬁ  cance. More than 10 cells were counted.
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